Receptor-mediated gene delivery using the Fab fragments of anti-epidermal growth factor receptor antibodies: Improved immunogene approach

Jiabing Chen, Shinobu Gamou, Atsushi Takayanagi, Yuichiro Ohtake, Masafumi Ohtsubo, Nobuyoshi Shimizu

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We previously developed the "immunogene" approach toward cancer gene therapy using epidermal growth factor receptor (EGFR)-mediated endocytosis. Here, we describe an improved immunogene system, in which the antigen-binding (Fab) fragments of the monoclonal antibody (Ab) B4G7 against the human EGFR were conjugated with poly-L-lysine to form a gene delivery vehicle (designated Fab "immunoporter"). Within 12 hours, the β-galactosidase (β-gal) gene was transferred via the Fab immunoporter to virtually all of the nuclei of human squamous carcinoma A431 cells that overproduce the EGFR, and the β-gal enzyme activity was detected within 24 hours and retained for more than 3 days. The β-gal gene was not transferred into human and mouse cells that were deficient in EGFRs, but it was delivered if those mouse cells were transformed with human EGFR genes. β-gal gene transfer via the Fab immunoporter was inhibited by pretreatment with excess amounts of the Fab fragment. The transfer efficiency of the β-gal gene to A431 cells via the Fab immunoporter was ∼2%, which is as high as the lipofection method and 20- to 100-fold higher than the whole Ab immunoporter. The transfer of the herpes simplex virus thymidine kinase gene into A431 tumor cells as a form of the thymidine kinase/Fab immunogene was successful, and subsequent treatment with ganciclovir induced remarkable suicide effects which conferred 1000-fold higher drug sensitivity. Thus, the Fab immunogene was substantially improved with regard to the whole Ab immunogene and could be used as a potent gene transfer vehicle for the in vivo targeting of EGFR-hyperproducing tumor cells.

Original languageEnglish
Pages (from-to)357-364
Number of pages8
JournalCancer Gene Therapy
Volume5
Issue number6
Publication statusPublished - 1998

Fingerprint

Immunoglobulin Fab Fragments
Epidermal Growth Factor Receptor
Antibodies
Genes
Thymidine Kinase
Galactosidases
erbB-1 Genes
Ganciclovir
Neoplasm Genes
Simplexvirus
Endocytosis
Genetic Therapy
Suicide
Lysine
Squamous Cell Carcinoma
Neoplasms
Monoclonal Antibodies
Antigens
Enzymes
Pharmaceutical Preparations

Keywords

  • Anti-epidermal growth factor receptor antibody
  • Endocytosis
  • Fab
  • Immunogene
  • Suicide gene

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Receptor-mediated gene delivery using the Fab fragments of anti-epidermal growth factor receptor antibodies : Improved immunogene approach. / Chen, Jiabing; Gamou, Shinobu; Takayanagi, Atsushi; Ohtake, Yuichiro; Ohtsubo, Masafumi; Shimizu, Nobuyoshi.

In: Cancer Gene Therapy, Vol. 5, No. 6, 1998, p. 357-364.

Research output: Contribution to journalArticle

Chen, J, Gamou, S, Takayanagi, A, Ohtake, Y, Ohtsubo, M & Shimizu, N 1998, 'Receptor-mediated gene delivery using the Fab fragments of anti-epidermal growth factor receptor antibodies: Improved immunogene approach', Cancer Gene Therapy, vol. 5, no. 6, pp. 357-364.
Chen, Jiabing ; Gamou, Shinobu ; Takayanagi, Atsushi ; Ohtake, Yuichiro ; Ohtsubo, Masafumi ; Shimizu, Nobuyoshi. / Receptor-mediated gene delivery using the Fab fragments of anti-epidermal growth factor receptor antibodies : Improved immunogene approach. In: Cancer Gene Therapy. 1998 ; Vol. 5, No. 6. pp. 357-364.
@article{35ae26553af54f36bbe12f0cab897012,
title = "Receptor-mediated gene delivery using the Fab fragments of anti-epidermal growth factor receptor antibodies: Improved immunogene approach",
abstract = "We previously developed the {"}immunogene{"} approach toward cancer gene therapy using epidermal growth factor receptor (EGFR)-mediated endocytosis. Here, we describe an improved immunogene system, in which the antigen-binding (Fab) fragments of the monoclonal antibody (Ab) B4G7 against the human EGFR were conjugated with poly-L-lysine to form a gene delivery vehicle (designated Fab {"}immunoporter{"}). Within 12 hours, the β-galactosidase (β-gal) gene was transferred via the Fab immunoporter to virtually all of the nuclei of human squamous carcinoma A431 cells that overproduce the EGFR, and the β-gal enzyme activity was detected within 24 hours and retained for more than 3 days. The β-gal gene was not transferred into human and mouse cells that were deficient in EGFRs, but it was delivered if those mouse cells were transformed with human EGFR genes. β-gal gene transfer via the Fab immunoporter was inhibited by pretreatment with excess amounts of the Fab fragment. The transfer efficiency of the β-gal gene to A431 cells via the Fab immunoporter was ∼2{\%}, which is as high as the lipofection method and 20- to 100-fold higher than the whole Ab immunoporter. The transfer of the herpes simplex virus thymidine kinase gene into A431 tumor cells as a form of the thymidine kinase/Fab immunogene was successful, and subsequent treatment with ganciclovir induced remarkable suicide effects which conferred 1000-fold higher drug sensitivity. Thus, the Fab immunogene was substantially improved with regard to the whole Ab immunogene and could be used as a potent gene transfer vehicle for the in vivo targeting of EGFR-hyperproducing tumor cells.",
keywords = "Anti-epidermal growth factor receptor antibody, Endocytosis, Fab, Immunogene, Suicide gene",
author = "Jiabing Chen and Shinobu Gamou and Atsushi Takayanagi and Yuichiro Ohtake and Masafumi Ohtsubo and Nobuyoshi Shimizu",
year = "1998",
language = "English",
volume = "5",
pages = "357--364",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Receptor-mediated gene delivery using the Fab fragments of anti-epidermal growth factor receptor antibodies

T2 - Improved immunogene approach

AU - Chen, Jiabing

AU - Gamou, Shinobu

AU - Takayanagi, Atsushi

AU - Ohtake, Yuichiro

AU - Ohtsubo, Masafumi

AU - Shimizu, Nobuyoshi

PY - 1998

Y1 - 1998

N2 - We previously developed the "immunogene" approach toward cancer gene therapy using epidermal growth factor receptor (EGFR)-mediated endocytosis. Here, we describe an improved immunogene system, in which the antigen-binding (Fab) fragments of the monoclonal antibody (Ab) B4G7 against the human EGFR were conjugated with poly-L-lysine to form a gene delivery vehicle (designated Fab "immunoporter"). Within 12 hours, the β-galactosidase (β-gal) gene was transferred via the Fab immunoporter to virtually all of the nuclei of human squamous carcinoma A431 cells that overproduce the EGFR, and the β-gal enzyme activity was detected within 24 hours and retained for more than 3 days. The β-gal gene was not transferred into human and mouse cells that were deficient in EGFRs, but it was delivered if those mouse cells were transformed with human EGFR genes. β-gal gene transfer via the Fab immunoporter was inhibited by pretreatment with excess amounts of the Fab fragment. The transfer efficiency of the β-gal gene to A431 cells via the Fab immunoporter was ∼2%, which is as high as the lipofection method and 20- to 100-fold higher than the whole Ab immunoporter. The transfer of the herpes simplex virus thymidine kinase gene into A431 tumor cells as a form of the thymidine kinase/Fab immunogene was successful, and subsequent treatment with ganciclovir induced remarkable suicide effects which conferred 1000-fold higher drug sensitivity. Thus, the Fab immunogene was substantially improved with regard to the whole Ab immunogene and could be used as a potent gene transfer vehicle for the in vivo targeting of EGFR-hyperproducing tumor cells.

AB - We previously developed the "immunogene" approach toward cancer gene therapy using epidermal growth factor receptor (EGFR)-mediated endocytosis. Here, we describe an improved immunogene system, in which the antigen-binding (Fab) fragments of the monoclonal antibody (Ab) B4G7 against the human EGFR were conjugated with poly-L-lysine to form a gene delivery vehicle (designated Fab "immunoporter"). Within 12 hours, the β-galactosidase (β-gal) gene was transferred via the Fab immunoporter to virtually all of the nuclei of human squamous carcinoma A431 cells that overproduce the EGFR, and the β-gal enzyme activity was detected within 24 hours and retained for more than 3 days. The β-gal gene was not transferred into human and mouse cells that were deficient in EGFRs, but it was delivered if those mouse cells were transformed with human EGFR genes. β-gal gene transfer via the Fab immunoporter was inhibited by pretreatment with excess amounts of the Fab fragment. The transfer efficiency of the β-gal gene to A431 cells via the Fab immunoporter was ∼2%, which is as high as the lipofection method and 20- to 100-fold higher than the whole Ab immunoporter. The transfer of the herpes simplex virus thymidine kinase gene into A431 tumor cells as a form of the thymidine kinase/Fab immunogene was successful, and subsequent treatment with ganciclovir induced remarkable suicide effects which conferred 1000-fold higher drug sensitivity. Thus, the Fab immunogene was substantially improved with regard to the whole Ab immunogene and could be used as a potent gene transfer vehicle for the in vivo targeting of EGFR-hyperproducing tumor cells.

KW - Anti-epidermal growth factor receptor antibody

KW - Endocytosis

KW - Fab

KW - Immunogene

KW - Suicide gene

UR - http://www.scopus.com/inward/record.url?scp=0032199731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032199731&partnerID=8YFLogxK

M3 - Article

C2 - 9917090

AN - SCOPUS:0032199731

VL - 5

SP - 357

EP - 364

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 6

ER -